RCTs on Cannabinoids for Movement Disorders Show Mixed Results Across Conditions

In Parkinson's disease, no RCT showed motor symptom improvement, though nabilone improved quality of life and reduced dyskinesia in one trial. Both Tourette syndrome RCTs showed tic improvement. Only one of three Huntington's disease RCTs found symptom relief. Neither dystonia RCT showed benefit.

Systematic review of all published randomized controlled trials on cannabinoids in movement disorders. Identified 7 RCTs on Parkinson's disease, 2 on Tourette syndrome, 3 on Huntington's disease, and 2 on dystonia. Different cannabis formulations were used across studies.

Movement disorders are often difficult to treat, and patients frequently ask about cannabis. This review provides an evidence-based summary of what RCTs actually show, which is considerably more nuanced than anecdotal reports suggest.

The pattern across conditions is telling: cannabinoids seem most promising for Tourette syndrome and some non-motor symptoms of Parkinson's, but the small number and size of trials make definitive conclusions impossible. The authors emphasize the urgent need for better-designed trials.

The total number of RCTs is small, and the trials themselves had small sample sizes. Different cannabinoid formulations were used across studies, making comparison difficult. Publication bias may favor positive results.